drugset / Trial / NCT00876850
Phase 3 Study - Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A Phase III trial to demonstrate the safety and efficacy of PTK 0796 in the treatment of complicated skin and skin structure infections (cSSSI).
Timeline
- Start
- 2009-07
- Primary completion
- 2010-07
- Completion
- 2010-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Linezolid | Other / unclassified | 600 mg | Oral |
| Subject | Moxifloxacin | Small molecule | 400 mg | Oral |
| Subject | Omadacycline | Small molecule | 100 mg | Intravenous |
| Subject | Omadacycline | Small molecule | 150 mg | Intravenous |
Indications
No indication recorded.